Therapeutic potential of copper chelation with triethylenetetramine in managing diabetes mellitus and alzheimers disease

Drugs

Volumn 71, Issue 10, 2011, Pages 1281-1320

  Cooper, Garth J S ^a,b,c,d  

^a MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Alzheimers disease; arteriosclerosis; Copper overload; diabetes; diabetic arteriopathy; diabetic nephropathy; diabetic neuropathy; diabetic retinopathy; experimental pharmacology; experimental therapeutics; heart failure; iron; organ regeneration; oxidative stress; randomized clinical trials; selective copper chelation; triethylenetetramine; zinc

Indexed keywords

3 DEOXYGLUCOSONE; 8 HYDROXYDEOXYGUANOSINE; ACYLTRANSFERASE; ADENOSINE TRIPHOSPHATASE; ADVANCED GLYCATION END PRODUCT; AMINE OXIDASE (COPPER CONTAINING); AQUAPORIN 1; ARYLAMINE ACETYLTRANSFERASE; COLLAGEN TYPE 1; COLLAGEN TYPE 3; COLLAGEN TYPE 4; COPPER; COPPER ZINC SUPEROXIDE DISMUTASE; DRUG METABOLITE; ENDOTHELIUM DERIVED HYPERPOLARIZING FACTOR; EXTRACELLULAR SUPEROXIDE DISMUTASE; FIBRONECTIN; HEPARAN SULFATE; METHYLGLYOXAL; N1 ACETYLTRIETHYLENETETRAMINE; N1,N10 DIACETYLTRIETHYLENETETRAMINE; PENICILLAMINE; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; REACTIVE OXYGEN METABOLITE; SMAD4 PROTEIN; TETRATHIOMOLYBDATE AMMONIUM; TRANSFORMING GROWTH FACTOR BETA1; TRIENTINE; UNCLASSIFIED DRUG; ZINC;

ACETYLATOR PHENOTYPE; ALZHEIMER DISEASE; ANTIOXIDANT ACTIVITY; ARTERIOSCLEROSIS; BLOOD VESSEL WALL; CARDIOVASCULAR DISEASE; CHELATION THERAPY; CHEMICAL MODIFICATION; CHRONIC TOXICITY; CLINICAL TRIAL (TOPIC); CONNECTIVE TISSUE; COPPER CHELATION; COPPER DEFICIENCY; COPPER METABOLISM; COPPER OVERLOAD; CORONARY ARTERY BLOOD FLOW; CRYSTAL STRUCTURE; DEGENERATIVE DISEASE; DEMENTIA; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETOGENESIS; DISEASE ASSOCIATION; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; HEART DISEASE; HEART LEFT VENTRICLE HYPERTROPHY; HEMATOLOGIC DISEASE; HOMEOSTASIS; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INTOXICATION; IRON METABOLISM; METABOLIC DISORDER; METAL BINDING; MOLECULAR DYNAMICS; MULTIINFARCT DEMENTIA; NERVE DEGENERATION; NEUROPATHOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; PROTEINURIA; PROTEOMICS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REGULATORY MECHANISM; REVIEW; STREPTOZOCIN DIABETES; TISSUE INJURY; WILSON DISEASE; ZINC METABOLISM;

ALZHEIMER DISEASE; ANIMALS; CHELATING AGENTS; COPPER; DIABETES COMPLICATIONS; DIABETES MELLITUS; DRUG DELIVERY SYSTEMS; HUMANS; TRIENTINE;

ANIMALIA;

EID: 79960497233     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11591370-000000000-00000     Document Type: Review

References (283)

1. Wolff SP, Jiang ZY, Hunt JV. Protein glycation and oxidative stress in diabetes mellitus and ageing. Free Radic Biol Med 1991; 10 (5): 339-52. (Pubitemid 121003905)
2. Wolff SP. Diabetes mellitus and free radicals: free radicals, transition metals and oxidative stress in the aetiology of diabetes mellitus and complications. Br Med Bull 1993 Jul; 49 (3): 642-52. (Pubitemid 23243836)
3. Monnier VM. Transition metals redox: reviving an old plot for diabetic vascular disease. J Clin Invest 2001 Apr; 107 (7): 799-801. (Pubitemid 32274032)
4. Thomas MC, Baynes JW, Thorpe SR, et al. The role of AGEs and AGE inhibitors in diabetic cardiovascular disease. Curr Drug Targets 2005; 6: 453-74. (Pubitemid 40916272)
5. Mattson MP, Magnus T. Ageing and neuronal vulnerability. Nat Neurosci 2006; 7: 278-94.
6. Martinez A, Portero-Otin M, Pamplona R, et al. Protein targets of oxidative damage in human neurodegenerative diseases with abnormal protein aggregates. Brain Pathol 2010 Mar; 20 (2): 281-97.
7. Forbes JM, Coughlan MT, Cooper ME. Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes 2008 Jun; 57 (6): 1446-54.
8. Halliwell B, Gutteridge JMC. Free radicals in biology and medicine. 4th ed. Oxford: Oxford University Press, 2007.
9. Gil JM, Rego AC. Mechanisms of neurodegeneration in Huntington's disease. Eur J Neurosci 2008 Jun; 27 (11): 2803-20. (Pubitemid 351832229)
10. Browne SE, Ferrante RJ, Beal MF. Oxidative stress in Huntington's disease. Brain Pathol 1999 Jan; 9 (1): 147-63. (Pubitemid 29056525)
11. Barber SC, Shaw PJ. Oxidative stress in ALS: key role in motor neuron injury and therapeutic target. Free Rad Biol Med 2010; 48: 629-41.
12. Janson J, Laedtke T, Parisi JE, et al. Increased risk of type 2 diabetes in Alzheimer disease. Diabetes 2004 Feb; 53 (2): 474-81. (Pubitemid 38174565)
13. Cooper GJS, Aitken JF, Zhang S. Is type 2 diabetes an amyloidosis and does it really matter (to patients)? Diabetologia 2010; 53: 1011-6.
14. Zhang S, Liu H, Yu H, et al. Fas-associated death receptor signaling evoked by human amylin in islet beta-cells. Diabetes 2008 Feb; 57 (2): 348-56.
15. Aitken JF, Loomes KM, Scott DW, et al. Tetracycline treatment retards the onset and slows the progression of diabetes in human amylin/islet amyloid polypeptide transgenic mice. Diabetes 2010 Jan; 59 (1): 161-71.
16. Panel on Dietary Antioxidants and Related Compounds, Subcommittees on Upper Reference Levels of Nutrients and of Interpretation and Use of Dietary Reference Intakes on Upper Reference Levels of Nutrients and Interpretation and Uses of DRIs, Standing Committee on the Scientific Evaluation of Dietary Reference Intakes, Food and Nutrition Board. Dietary reference intakes for vitamin C, vitamin E, selenium, and carotenoids. Washington, DC: National Academy of Sciences, 2000.
17. Yusuf S, Dagenais G, Pogue J, et al., The Heart Outcomes Prevention Evaluation Study Investigators. Vitamin E supplementation and cardiovascular events in high-risk patients. N Engl J Med 2000 Jan 20; 342 (3): 154-60. (Pubitemid 30051646)
18. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 23-33.
19. Roberts AB, McCune BK, Dunn SR. TGF-b: regulation of extracellular matrix. Kidney Int 1992; 41: 557-9.
20. Gong D, Lu J, Chen X, et al. Molecular changes evoked by triethylenetetramine treatment in the extracellular matrix of the heart and aorta in diabetic rats. Mol Pharmacol 2006 Dec; 70 (6): 2045-51. (Pubitemid 44771920)
21. Pohlers D, Brenmoehl J, Loffler I, et al. TGF-beta and fibrosis in different organs-molecular pathway imprints. Biochim Biophys Acta 2009 Aug; 1792 (8): 746-56.
22. Roth M. "Glycated hemoglobin," not "glycosylated" or "glucosylated" [letter]. Clin Chem 1983 Nov; 29 (11): 1991.
23. Ahmed MU, Thorpe SR, Baynes JW. Identification of N epsilon- carboxymethyllysine as a degradation product of fructoselysine in glycated protein. J Biol Chem 1986 Apr 15; 261 (11): 4889-94. (Pubitemid 17204276)
24. Brownlee M, Vlassara H, Cerami A. Nonenzymatic glycosylation and pathogenesis of diabetes complications. Ann Intern Med 1984; 101: 527-37. (Pubitemid 14018054)
25. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988 May 19; 318 (20): 1315-21.
26. Baynes JW, Thorpe SR. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 1999 Jan; 48 (1): 1-9. (Pubitemid 29019345)
27. Monnier VM, Sell DR. Prevention and repair of protein damage by the Maillard reaction in vivo. Rejuvenation Res 2006; 9 (2): 264-73. (Pubitemid 43856818)
28. Smith MA, Taneda S, Richey PL, et al. Advanced Maillard reaction end products are associated with Alzheimer disease pathology. Proc Natl Acad SciUSA 1994; 91: 5710-4. (Pubitemid 24174398)
29. Sasaki N, Fukatsu R, Tsuzuki K, et al. Advanced glycation end products in Alzheimer's disease and other neurodegenerative diseases. Am J Pathol 1998 Oct; 153 (4): 1149-55. (Pubitemid 28465838)
30. Schleicher ED, Wagner E, Nerlich AG. Increased accumulation of the glycoxidation product N-epsilon-(carboxymethyl) lysine in human tissues in diabetes and aging. J Clin Invest 1997; 99 (3): 457-68. (Pubitemid 27414803)
31. Qian M, Liu M, Eaton JW. Transition metals bind to glycated proteins forming redox active "glycochelates": implications for the pathogenesis of certain diabetic complications. Biochem Biophys Res Commun 1998 Sep 18; 250 (2): 385-9. (Pubitemid 28463887)
32. Saxena AK, Saxena P, Wu X, et al. Protein aging by carboxymethylation of lysines generates sites for divalent metal and redox active copper binding: relevance to diseases of glycoxidative stress. Biochem Biophys Res Commun 1999 Jul 5; 260 (2): 332-8. (Pubitemid 29352066)
33. Qian M, Eaton JW. Glycochelates and the etiology of diabetic peripheral neuropathy. Free Radic Biol Med 2000; 28: 652-6. (Pubitemid 30136047)
34. Eaton JW, Qian M. Interactions of copper with glycated proteins: possible involvement in the etiology of diabetic neuropathy. Mol Cell Biochem 2002 May-Jun; 234-5 (1-2): 135-42. (Pubitemid 34777850)
35. Hamada Y, Nakashima E, Naruse K, et al. A copper chelating agent suppresses carbonyl stress in diabetic rat lenses. J Diabetes Complications 2005 Nov-Dec; 19 (6): 328-34. (Pubitemid 41563015)
36. Seifert ST, Krause R, Gloe K, et al. Metal complexation by the peptide-bound Maillard reaction products N-e-fructoselysine and N-e-carboxymethyllysine. J Ag Food Chem 2004; 52: 2347-50.
37. Nishikawa T, Edelstein D, Du XL, et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000 Apr 13; 404 (6779): 787-90. (Pubitemid 30212409)
38. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001 Dec 13; 414 (6865): 813-20. (Pubitemid 34000785)
39. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005 Jun; 54 (6): 1615-25. (Pubitemid 40770750)
40. Semba RD, Beck J, Sun K, et al. Relationship of a dominant advanced glycation end product, serum carboxymethyl-lysine, and abnormal glucose metabolism in adults: the Baltimore Longitudinal Study of Aging. JNutr Health Aging 2010; 14 (7): 507-13.
41. Kadiiska MB, Hanna PM, Hernandez L, et al. In vivo evidence of hydroxyl radical formation after acute copper and ascorbic acid intake: electron spin resonance spintrapping investigation. Mol Pharmacol 1992; 42: 723-9. (Pubitemid 23027639)
42. CooperGJS, Phillips ARJ, Choong SY, et al. Regeneration of the heart in diabetes by selective copper chelation. Diabetes 2004 Sep; 53 (9): 2501-8. (Pubitemid 39145611)
43. Cooper GJ, Young AA, Gamble GD, et al. A copper(II)-selective chelator ameliorates left-ventricular hypertrophy in type 2 diabetic patients: a randomised placebocontrolled study. Diabetologia 2009 Apr; 52 (4): 715-22.
44. Fraústo da Silva JJ, Williams RJ. The biological chemistry of the elements: the inorganic chemistry of life. 2nd ed. Oxford: Clarendon Press, 2001: 418-35.
45. Cooper GJS, Chan YK, Dissanayake AM, et al. Demonstration of a hyperglycemia-driven pathogenic abnormality of copper homeostasis in diabetes and its reversibility by selective chelation: quantitative comparisons between the biology of copper and eight other nutritionally essential elements in normal and diabetic individuals. Diabetes 2005 May; 54 (5): 1468-76. (Pubitemid 40586679)
46. Ferri CP, Prince M, Brayne C, et al. Global prevalence of dementia: a Delphi consensus study. Lancet 2005; 366: 2112-7. (Pubitemid 41797645)
47. Launer LJ. Demonstrating the case that AD is a vascular disease: epidemiologic evidence. Ageing Res Rev 2002; 1: 61-77. (Pubitemid 38340352)
48. Luchsinger JA, Tang MX, Stern Y, et al. Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort. Am J Epidemiol 2001 Oct 1; 154 (7): 635-41. (Pubitemid 32888781)
49. Skoog I. Status of risk factors for vascular dementia. Neuroepidemiology 1998; 17 (1): 2-9. (Pubitemid 28153359)
50. Skoog I, Kalaria RN, Breteler MMB. Vascular factors and Alzheimer disease. Alzheimer Dis Assoc Disord 1999; 13: S106-S14.
51. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 2000 Feb 10; 342 (6): 381-9.
52. DCCT/EDIC Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. J Am Med Assoc 2002; 287: 2563-9.
53. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes.NEngl JMed 2005; 353 (25): 2643-53.
54. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998 Sep 12; 352 (9131): 837-53.
55. Oresic M, Simell S, Sysi-Aho M, et al. Dysregulation of lipid and amino acid metabolism precedes islet autoimmunity in children who later progress to type 1 diabetes. J Exp Med 2008; 205 (13): 2975-84.
56. Duckworth W, Abraira C, Moritz T. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360 (2): 129-39.
57. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008 Jun 12; 358 (24): 2545-59. (Pubitemid 351831356)
58. Holman RR, Paul SK, Bethel MA, et al. Ten-year followup of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 358: 1577-89.
59. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.N Engl J Med 2008 Jun 12; 358 (24): 2560-72. (Pubitemid 351831357)
60. Gaede P, Lund-Andersen H, Parving HH, et al. Effect of a multifactorial intervention onmortality in type 2 diabetes. N Engl J Med 2008; 358: 580-91. (Pubitemid 351214285)
61. Mohamed Q, Gillies MC, Wong TY. Management of diabetic retinopathy: a systematic review. J Am Med Assoc 2007; 298: 902-16. (Pubitemid 47311296)
62. The ACCORD Study Group, Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010; 362 (17): 1563-74.
63. Rosca MG, Mustata TG, Kinter MT, et al. Glycation of mitochondrial proteins from diabetic rat kidney is associated with excess superoxide formation. Am J Physiol Renal Physiol 2005 Aug; 289 (2): F420-30.
64. Lu J, Gong D, Choong SY, et al. Copper(II)-selective chelation improves function and antioxidant defences in cardiovascular tissues of rats as a model of diabetes: comparisons between triethylenetetramine and three less copper-selective transition-metal-targeted treatments. Diabetologia 2010 Jun; 53 (6): 1217-26.
65. Feder JN, Gnirke A, Thomas W, et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 1996; 13: 399-408. (Pubitemid 26256612)
66. Buja LM, Roberts WC. Iron in the heart: etiology and clinical significance. Am J Med Genet 1971; 51: 209-21.
67. Telfer PT, Prestcott E, Holden S, et al. Hepatic iron concentration combined with long-term monitoring of serum ferritin to predict complications of iron overload in thalassaemia major. Br J Haematol 2002; 110: 971-7.
68. Gong D, Lu J, Chen X, et al. A copper(II)-selective chelator ameliorates diabetes-evoked renal fibrosis and albuminuria, and suppresses pathogenic TGF-beta activation in the kidneys of rats used as a model of diabetes. Diabetologia 2008 Sep; 51 (9): 1741-51.
69. Cameron NE, Cotter MA. Effects of an extracellular metal chelator on neurovascular function in diabetic rats. Diabetologia 2001 May; 44 (5): 621-8. (Pubitemid 32411279)
70. Cameron NE, Cotter MA. Neurovascular dysfunction in diabetic rats: potential contribution of autoxidation and free radicals examined using transition metal chelating agents. J Clin Invest 1995 Aug; 96 (2): 1159-63.
71. Inkster ME, Cotter MA, Cameron NE. Effects of trientine, a metal chelator, on defective endothelium-dependent relaxation in the mesenteric vasculature of diabetic rats. Free Radic Res 2002 Oct; 36 (10): 1091-9.
72. Keegan A, Cotter MA, Cameron NE. Effects of chelator treatment on aorta and corpus cavernosum from diabetic rats. Free Radic Biol Med 1999 Sep; 27 (5-6): 536-43. (Pubitemid 29408639)
73. Olivieri NF, Brittenham GM, McLaren CE, et al. Longterm safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. N Engl J Med 1998; 339: 417-23. (Pubitemid 28377682)
74. Dahlman T, Hartvig P, Lofholm M, et al. Long-term treatment of Wilson's disease with triethylene tetramine dihydrochloride (trientine). Q J Med 1995; 88: 609-16.
75. Kopp SJ, Klevay LM, Feliksik JM. Physiological and metabolic characterization of a cardiomyopathy induced by chronic copper deficiency. Am J Physiol Heart Circ Physiol 1983; 245: H855-66. (Pubitemid 14245490)
76. Saari JT. Copper deficiency and cardiovascular disease: role of peroxidation, glycation, and nitration. Can J Physiol Pharmacol 2000 Oct; 78 (10): 848-55.
77. Saari JT, Schuschke DA. Cardiovascular effects of dietary copper deficiency. Biofactors 1999; 10: 359-75.
78. Jaksch M, Horvath R, Horn N, et al. Homozygosity (E140K) in SCO2 causes delayed infantile onset of cardiomyopathy and neuropathy. Neurol 2001; 57: 1440-6. (Pubitemid 32995726)
79. Jaksch M, Ogilvie I, Yao J, et al. Mutations in SCO2 are associated with a distinct form of hypertrophic cardiomyopathy and cytochrome C oxidase deficiency. Hum Mol Genet 2000; 9: 795-801. (Pubitemid 30162764)
80. Jaksch M, Paret C, Stucka R, et al. Cytochrome c oxidase deficiency due to mutations in SCO2, encoding a mitochondrial copper-binding protein, is rescued by copper in human myoblasts. Hum Mol Genet 2001; 10: 3025-35. (Pubitemid 34083489)
81. Ferns GA, Lamb DJ, Taylor A. The possible role of copper ions in atherogenesis: the Blue Janus. Atheroscler 1997; 133: 139-52. (Pubitemid 27373491)
82. Culotta VC, Gitlin JD. Disorders of copper transport. In: Scriver CR, Beaudet AL, Sly WS, et al., editors. The metabolic and molecular bases of inherited disease. 8th ed. New York: McGraw-Hill, 2001: 3105-26.
83. Harris ED. Basic and clinical aspects of copper. Crit Rev Clin Lab Sci 2003 Oct; 40 (5): 547-86. (Pubitemid 37449503)
84. Finney LA, O'Halloran TV. Transition metal speciation in the cell: insights from the chemistry of metal ion receptors. Science 2003; 300: 931-6. (Pubitemid 36548870)
85. Huffman DL, O'Halloran TV. Function, structure, and mechanism of intracellular copper trafficking proteins. Annu Rev Biochem 2001; 70: 677-701. (Pubitemid 32662222)
86. Linder MC, Hazegh-Azam M. Copper biochemistry and molecular biology. Am J Clin Nutr 1996; 63 Suppl.: 797-811S.
87. Peña MM, Lee J, Thiele DJ. A delicate balance: homeostatic control of copper uptake and distribution. J Nutr 1999; 129: 1251-60.
88. Rae TD, Schmidt PJ, Pufahl RA, et al. Undetectable intracellular free copper: the requirement of a copper chaperone for superoxide dismutase. Science 1999; 284: 805-8. (Pubitemid 29291346)
89. Iskandar M, Swist E, Trick KD, et al. Copper chaperone for Cu/Zn superoxide dismutase is a sensitive biomarker of mild copper deficiency induced by moderately high intakes of zinc. Nutr J 2005; 4: 35.
90. Wang J, Song Y, Elsherif L, et al. Cardiac metallothionein induction plays the major role in the prevention of diabetic cardiomyopathy by zinc supplementation. Circulation 2006 Jan 31; 113 (4): 544-54.
91. Lutsenko S, Barnes NL, Bartree ME, et al. Function and regulation of human copper-transporting ATPases. Physiol Rev 2007; 87: 1011-46. (Pubitemid 47084675)
92. Tanzi RE, Petrukhin K, Chernov I, et al. The Wilson disease gene is a copper transporting ATPase with homology to the Menke's disease gene. Nat Genet 1993; 5: 344-50. (Pubitemid 23351304)
93. Dameron CT, Harrison MD. Mechanisms for protection against copper toxicity. Am J Clin Nutr 1998; 67 Suppl.: 1091S-7S. (Pubitemid 28198839)
94. Turnlund JR, Keyes WR, Anderson HL, et al. Copper absorption and retention in young men at three levels of dietary copper by use of the stable isotope 65Cu.AmJ Clin Nutr 1989; 1989: 870-8. (Pubitemid 19139791)
95. Turnlund JR, Jacob RA, Keen CL, et al. Long-term high copper intake: effects on indexes of copper status, antioxidant status, and immune function in young men. Am J Clin Nutr 2004; 79 (6): 1037-44. (Pubitemid 41095956)
96. Panel on Micronutrients, Subcommittees on Upper Reference Levels of Nutrients and of Interpretation and Use of Dietary Reference Intakes, and the Standing Committee on the Scientific Evaluation of Dietary Reference Intakes, Institute of Medicine. Dietary reference intakes for vitamin A, vitamin K, arsenic, boron, chromium, copper, iodine, iron, manganese, molybdenum, nickel, silicon, vanadium, and zinc. Washington, DC: National Academy of Sciences, 2001.
97. Turnlund JR, Keyes WR, Peiffer GL, et al. Copper absorption, excretion and retention by young men consuming low dietary copper, determined by using the stable isotope 65Cu. Am J Clin Nutr 1998; 67: 1219-25. (Pubitemid 28259510)
98. Moriya M, Ho YH, Grana A, et al. Copper is taken up efficiently from albumin and alpha2-macroglobulin by cultured human cells by more than one mechanism. Am J Physiol Cell Physiol 2008 Sep; 295 (3): C708-21.
99. Liu N, Lo LS, Askary SH, et al. Transcuprein is a macroglobulin regulated by copper and iron availability. J Nutr Biochem 2007 Sep; 18 (9): 597-608. (Pubitemid 47212710)
100. LinderMC. Biochemistry of copper.NewYork: Plenum, 1991.
101. Linder MC, Wooten L, Cerveza P, et al. Copper transport. Am J Clin Nutr 1998 May; 67 (5 Suppl.): 965-71S.
102. Zaitseva I, Zaitsev V, Cara G, et al. The X-ray structure of human ceruloplasmin at 3.1 D resolution: nature of the copper centers. J Biol Inorgan Chem 1996; 1: 15-23. (Pubitemid 126489977)
103. Gitlin JD. Aceruloplasminemia. Pediatr Res 1998; 44 (3): 271-6. (Pubitemid 28389977)
104. Hellman NE, Schaefer M, Gehrke S, et al. Hepatic iron overload in aceruloplasminaemia. Gut 2000; 47 (6): 858-60.
105. Hellman NE, Gitlin JD. Ceruloplasmin metabolism and function. Annu Rev Nutr 2002; 22: 439-58. (Pubitemid 35221468)
106. Nittis T, Gitlin JD. The copper-iron connection: hereditary aceruloplasminemia. Semin Hematol 2002; 39: 282-9.
107. Turnlund JR. Copper. In: Shils ME, Olson JA, Shike M, et al., editors. Modern nutrition in health and disease. 9th ed. Baltimore (MD): Williams and Wilkins, 1998: 241-52.
108. Cordano A. Clinical manifestations of nutritional copper deficiency in infants and children. Am J Clin Nutr 1998; 67 (5 Suppl.): 1012-6S.
109. Panel on Micronutrients, Subcommittees on Upper Reference Levels of Nutrients and of Interpretation and Use of Dietary Reference Intakes, and the Standing Committee on the Scientific Evaluation of Dietary Reference Intakes, Institute of Medicine. Dietary reference intakes for vitamin A, vitamin K, arsenic, boron, chromium, copper, iodine, iron, manganese, molybdenum, nickel, silicon, vanadium, and zinc. Washington, DC: National Academy of Sciences, 2002: 224-57.
110. Bennetts HW, Beck AB. Enzootic ataxia and copper deficiency of sheep in Western Australia. Aust Commonwealth Sci Ind Res Bull 1942; 147: 1-52.
111. Innes JRM. Swayback: a demyelinating disease of lambs with affinities to Schilder's encephalitis and its prevention by copper. J Neurol Psychiatr 1939; 147: 323-34.
112. Elsherif L, Wang L, Saari JT, et al. Regression of dietary copper restriction-induced cardiomyopathy by copper repletion in mice. J Nutr 2004; 134: 855-60. (Pubitemid 38456254)
113. Zidar BL, Saddrich RK, Zeigher Z, et al. Observations on the anemia and neutropenia of human copper deficiency. Am J Hematol 1977; 3: 177-85. (Pubitemid 8261717)
114. Dawson R, Milne G, Williams A. Changes in the collagen of rat heart in copper-deficiency-induced cardiac hypertrophy. Cardiovasc Res 1982; 16: 559-65. (Pubitemid 13242327)
115. Hill KE, Davidson JM. Induction of increased collagen and elastin biosynthesis in copper-deficient pig aorta. Atheroscler 1986; 6: 98-104. (Pubitemid 16154617)
116. Hawk SN, Uriu-Hare JY, Daston GP, et al. Rat embryos cultured under copper-deficient conditions develop abnormally and are characterized by an impaired oxidant defense system. Teratology 1998; 57: 310-20. (Pubitemid 28362548)
117. Yang SL,Keen CL, Lanoue L, et al. Low nitric oxide: a key factor underlying copper deficiency teratogenicity. Free Radic Biol Med 2007; 43: 1639-48. (Pubitemid 350122989)
118. Yamamoto M, Aklyama C, Alkawa H. D-Penicillamineinduced copper deficiency in suckling mice: neurological abnormalities and brain mitochondrial enzyme activities. Dev Brain Res 1990; 55: 51-5. (Pubitemid 20241303)
119. Bennetts HW, Chapman FE. Copper deficiency in sheep in Western Australia: a preliminary account of the etiology of enzootic ataxia of lambs and an anaemia of ewes. Aust Vet J 1937; 13: 138-49.
120. Roberts HE, Williams BM, Harvard A. Cerebral oedema in lambs associated with hypocuprosis, and its relationship to swayback: I. Field, clinical, gross anatomical and biochemical observations. J Comp Pathol 1966; 76: 279-83.
121. Chalmers GA. Swayback (enzootic ataxia) in Alberta lambs. Can J Comp Pathol 1974; 38: 111-7.
122. Percival SS. Neutropenia caused by copper deficiency. Nutr Rev 1995; 53: 59-66.
123. Lewis G, Terlecki S, Allcroft R. The occurrence of swayback in the lambs of ewes fed a semipurified diet of low copper content. Vet Rec 1967; 81: 415-6.
124. Mills CF, Fell BF. Demyelination in lambs born of ewes maintained on high intakes of sulphate and molybdate. Nature 1960; 185: 20-2.
125. Frank A, Danielsson R, Jones B. Experimental copper and chromium deficiency and additional molybdenum supplementation in goats: II. Concentrations of trace and minor elements in liver, kidneys and ribs: haematology and clinically chemistry. Sci Total Environ 2000; 249: 143-70. (Pubitemid 30190294)
126. Flynn AA, Franzman AW, Arneson PD, et al. Indications of copper deficiency in a subpopulation of Alaska moose. J Nutr 1977; 107: 1182-9. (Pubitemid 8146404)
127. Frank A, Sell DR, Danielsson R, et al. A syndrome of molybdenosis, copper deficiency, and type 2 diabetes in the moose population of south-west Sweden. Sci Total Environ 2000 Apr 17; 249 (1-3): 123-31. (Pubitemid 30190292)
128. Gogan PJP, Jessup DA, Akeson M. Copper deficiency in tule elk at Point Reyes, California. J Range Management 1989; 42: 233-8.
129. Wildman RE, Medeiros DM, Hamlin RL, et al. Aspects of cardiomyopathy in copper-deficient pigs: electrocardiography, echocardiography, and ultrastructural findings. Biol Trace Elem Res 1996; 55: 55-70. (Pubitemid 26427754)
130. Coulson WF, Carnes WWH. Cardiovascular studies on copper-deficient swine: XIII. The effect of chronic copper deficiency on the cardiovascular system of miniature pigs. Lab Invest 1962; 11: 1316-21.
131. Weissman N, Shields G, Carnes W. Cardiovascular studies on copper-deficient swine: IV. Content and solubility of the aortic elastin, collagen and hexosamine. J Biol Chem 1963; 238: 3115-8.
132. Linker A, Coulson W, Carnes W. Cardiovascular studies on copper-deficient swine: VI. The mucopolysaccharide composition of aorta and cartilage. J Biol Chem 1964; 239: 1690-3.
133. Viestenz KE, Klevay LM. A randomized trial of copper therapy in rats with electrocardiographic abnormalities due to copper deficiency. Am J Clin Nutr 1982; 35: 258-66. (Pubitemid 12121023)
134. Owen CAJ, Hazelrig JR. Copper deficiency and copper toxicity in the rat. Am J Physiol 1968; 215: 334-8.
135. Mao S,Medeiros DM, Wildman RE. Cardiac hypertrophy in copper-deficient rats is owing to increased mitochondria. Biol Trace Elem Res 1998; 64 (1-3): 175-84. (Pubitemid 28533339)
136. Kang YJ, Zhou ZX, Wu H, et al. Metallothionein inhibits myocardial apoptosis in copper-deficient mice: role of atrial natriuretic peptide. Lab Invest 2000 May; 80 (5): 745-57. (Pubitemid 30340659)
137. Klevay LM. Atrial thrombosis, abnormal electrocardiograms and sudden death in mice due to copper deficiency. Atherosclerosis 1985; 54: 213-24. (Pubitemid 15140096)
138. Song Y, Wang J, Li Y, et al. Cardiac metallothionein synthesis in streptozotocin-induced diabetic mice, and its protection against diabetes-induced cardiac injury. Am J Pathol 2005 Jul; 167 (1): 17-26. (Pubitemid 40884766)
139. Kang YJ,WuH, Saari JT. Alterations in hypertrophic gene expression by dietary copper restriction in mouse heart. Proc Soc Exp Biol Med 2000; 223: 282-7. (Pubitemid 30337783)
140. Tapia L, González-Aqüero M, Cisternas MF, et al. Metallothionein is crucial for safe intracellular copper storage and cell survival at normal and supra-physiological exposure levels. Biochem J 2004; 378 (Pt 2): 617-24. (Pubitemid 38367251)
141. Saari JT, Dahlen GM. Nitric oxide and cyclic GMP are elevated in the hearts of copper-deficient rats. Med Sci Res 1998; 26: 495-7. (Pubitemid 28379592)
142. Cartwright GE, Wintrobe MM. The question of copper deficiency in man. Am J Clin Nutr 1964; 94-110.
143. Danks DM. Copper deficiency in humans. Annu Rev Nutr 1988; 8: 235-57. (Pubitemid 19136326)
144. Danks DM. Disorders of copper transport. In: Scriver CR, Beaudet AL, SlyWS, et al., editors. The metabolic basis of inherited disease. 6th ed. New York: McGraw-Hill, 1989: 1411-31.
145. Heller RM, Kirchner SG, O'Neill JA, et al. Skeletal changes of copper deficiency in infants receiving prolonged total parenteral nutrition. J Pediatr 1978; 92 (6): 947-9.
146. Karpel JT, Peden VH. Copper deficiency in long-term parenteral nutrition. J Pediatr 1972; 80 (1): 32-6.
147. Sutton AM, Harvie A, Cockburn F, et al. Copper deficiency in the preterm infant of very low birthweight: four cases and a reference range for plasma copper. Arch Dis Child 1985; 60: 644-51. (Pubitemid 15006928)
148. Graham GC, Cordano A. Copper depletion and deficiency in the malnourished infant. Johns Hopkins Med J 1969; 124: 39-50.
149. Cordano A, Graham GG. Copper deficiency complicating severe chronic malabsorption. Pediatr 1966; 38: 596-604.
150. Graham GG, Cordano A. Copper depletion and deficiency in the malnourished infant. Johns Hopkins Med J 1969; 124: 139-50.
151. Josephs HW. Treatment of anemia in infants with iron and copper. Bull Johns Hopkins Hosp 1931; 49: 246-54.
152. Peltonen L, Kuivaniem H, Palotie A, et al. Alterations of copper and collagen metabolism in theMenkes syndrome and a new subtype of Ehlers-Danlos Syndrome. Biochemistry 1983; 22: 6156-63. (Pubitemid 14175818)
153. Turnlund JR. Copper status and metabolism studied with isotopic tracers. In: Lowe N, Jackson M, editors. Advances in isotope methods for the analysis of trace elements in man. Boca Raton (FL): CRC Press, 2001: 117-27.
154. Mason KE.A conspectus of research on copper metabolism and requirements of man. J Nutr 1979; 109: 1979-2066. (Pubitemid 10185786)
155. Mertz W. The use and misuse of balance studies. J Nutr 1987; 117: 1811-3.
156. Turnlund JR, Scott KC, Peiffer GL, et al. Copper status of young men consuming a low copper diet. Am J Clin Nutr 1997; 65: 72-8. (Pubitemid 27020462)
157. Bremner I. Manifestations of copper excess. Am J Clin Nutr 1998; 67 Suppl.: 1069-73S.
158. Sriramachari S, Nayak NC. Indian childhood cirrhosis: several dilemmas resolved. Indian J Med Res 2008; 128: 93-6.
159. Muller T, Muller W, Feichtinger H. Idiopathic copper toxicosis. Am J Clin
160. Uriu-Adams JY, Keen CL. Copper, oxidative stress, and human health. Mol Aspects Med 2005 Aug-Oct; 26 (4-5): 268-98. (Pubitemid 41225353)
161. Turnlund JR, Keyes WR, Kim SK, et al. Long-term high copper intake: effects on copper absorption, retention, and homeostasis in men. Am J Clin Nutr 2005; 81: 822-8. (Pubitemid 41724989)
162. Turnlund JR, Domek JM, Nair PP, et al. Copper retention in intestinal musosal cells of young men at normal and high copper intakes. J Trace Elem ExpMed 2003; 16: 105-8. (Pubitemid 36927363)
163. Tanner MS. The role of copper in Indian childhood cirrhosis. Am J Clin Nutr 1998; 67 Suppl.: 1074-81S.
164. Wijmenga C, Müller T, Murli IS, et al. Endemic Tyrolean infantile cirrhosis is not an allelic variant of Wilson's disease. Eur J Hum Genet 1998; 6: 624-8. (Pubitemid 29020798)
165. Muller T, FeichtingerH, Berger H, et al. Endemic Tyrolean infantile cirrhosis: an ecogenetic disorder. Lancet 1996; 347: 877-80. (Pubitemid 26099543)
166. Yuzbasiyan-Gurkan V, Grider A, Nostrant T, et al. Treatment of Wilson's disease with zinc: X. Intestinal metallothionein induction. J Lab Clin Med 1992 Sep; 120 (3): 380-6.
167. Brewer GJ. Zinc acetate for the treatment of Wilson's disease. Exp Opin Pharmacotherap 2001; 2: 1473-7. (Pubitemid 32827417)
168. Allen MM, Harding JDJ. Experimental copper poisoning in pigs. Vet Rec 1962; 74: 173-9.
169. Fuentealba IC, Aburto EM. Animal models of copperassociated liver disease. Comp Hepatol 2003; 2: 5.
170. Fuentealba I, Haywood S, Foster J. Cellular mechanisms of toxicity and tolerance in the copper-loaded rat: II. Pathogenesis of copper toxicity in the liver. Exp Mol Pathol 1989; 50: 26-37. (Pubitemid 19079310)
171. Fuentealba IC, Davis RW, Elmes ME, et al. Mechanisms of tolerance in the copper-loaded rat liver. Exp Mol Pathol 1993; 59: 71-84. (Pubitemid 23257966)
172. Ishmael J, Gopinath C, Howell JM. Experimental chronic copper toxicity in sheep: biochemical and haematological studies during the development of changes in the liver. Res Vet Sci 1972; 13: 22-9.
173. Ishmael J, Gopinath C, Howell J. Experimental chronic copper toxicity in sheep: histological and histochemical changes during development of the changes in the liver. Res Vet Sci 1971; 12: 358-66.
174. Peña MM, Koch KA, Thiele DJ. Dynamic regulation of copper uptake and detoxification genes in Saccharomyces cerevisiae. Mol Cell Biol 1998; 18: 2514-23.
175. Furst P, Hu S, Hackett R, et al. Copper activates metallothionein gene transcription by altering the conformation of a specific DNA binding protein. Cell 1988 Nov 18; 55 (4): 705-17.
176. Gralla EB, Thiele DJ, Silar P, et al. ACE1, a copperdependent transcription factor, activates expression of the yeast copper, zinc superoxide dismutase gene of the yeast copper, zinc superoxide dismutase gene. Proc Natl Acad Sci USA 1991; 88: 8558-62. (Pubitemid 21915396)
177. Shinyashiki M, Chiang KT, Switzer CH, et al. The interaction of nitric oxide (NO) with the yeast transcription factor Ace1: a model system for NO-protein thiol interactions with implications to metal metabolism. Proc Natl Acad Sci USA 2000; 97 (6): 2491-6. (Pubitemid 30159198)
178. Georgatsou E, Mavrogiannis LA, Fragiadakis GS, et al. The yeast Fre1p/Fre2p cupric reductases facilitate copper uptake and are regulated by the copper-modulated Mac1p activator. J Biol Chem 1997; 272: 13786-92. (Pubitemid 27224817)
179. Gross C, Kelleher M, Iyer VR, et al. Identification of the copper regulon in Saccharomyces cerevisiae by DNA microarrays. J Biol Chem 2000; 275 (41): 32310-6.
180. Dameron CT, Harris ED. Regulation of aortic CuZnsuperoxide dismutase with copper: caeruloplasmin and albumin re-activate and transfer copper to the enzyme in culture. Biochem J 1987; 248: 669-75.
181. Dameron CT, Harris ED. Regulation of aortic CuZnsuperoxide dismutase with copper: effects in vivo. Biochem J 1987; 248: 663-8.
182. Thomas GR, Forbes JR, Roberts EA, et al. The Wilson disease gene: the spectrum of mutations and their consequences. Nat Genet 1995; 210-7.
183. Krajacic P, Qian Y, Hahn P, et al. Retinal localization and copper-dependent relocalization of the Wilson and Menkes disease proteins. Invest Ophthalmol Vis Sci 2006 Jul; 47 (7): 3129-34. (Pubitemid 351639792)
184. Kuan P. Cardiac Wilson's disease. Chest 1987; 91: 579-83. (Pubitemid 17058884)
185. Walshe JM. Copper chelation in patients with Wilson's disease: a comparison of penicillamine and triethylene tetramine dihydrochloride. Q J Med 1973; 42: 441-52.
186. Brewer GJ. Raulin Award Lecture: Wilson's disease therapy with zinc and tetrathiomolybdate. J Trace Elem Exp Med 2000; 13: 51-61. (Pubitemid 30088418)
187. Walshe JM. Treatment of Wilson's disease with trientine (triethylene tetramine) dihydrochloride. Lancet 1982 Mar 20; 1 (8273): 643-7. (Pubitemid 12179933)
188. Siegemund R, LöXner J, Günther K, et al. Mode of action of triethylenetetramine dihydrochloride on copper metabolism inWilson's disease. ActaNeurol Scand 1991; 83: 364-6.
189. Morita J, Yoshino M, Watari H, et al. Wilson's disease treatment by triethylene tetramine dihydrochloride (trientine, 2HCl): long-term observation. Dev Pharmacol Therap 1992; 19: 6-9. (Pubitemid 23187339)
190. Kodama H, Murata Y, Iitsuka T, et al. Metabolism of administered triethylene tetramine dihydrochloride in humans. Life Sci 1997; 61: 899-907. (Pubitemid 27339070)
191. Condamine L, Hermine O, Alvin P, et al. Acquired sideroblastic anaemia during treatment of Wilson's disease with triethylene tetramine dihydrochloride. Br J Haematol 1993; 83: 166-8. (Pubitemid 23030189)
192. Joyce DA. D-penicillamine. Baillières Clin Rheumatol 1990; 4: 553-74.
193. Keen CL, Mark-Savage P, Lonnerdal B, et al. Teratogenesis and low copper status resulting from D-penicillamine in rats. Teratology 1982; 26: 163-5. (Pubitemid 13203983)
194. Frank A. 'Mysterious' moose disease in Sweden: similarities to copper deficiency and/or molybdenosis in cattle and sheep. Biochemical background of clinical signs and organ lesions. Sci Tot Environ 1998; 209 (1): 17-26. (Pubitemid 28068697)
195. Frank A, Danielsson R, Jones B. The 'mysterious' disease in Swedish moose: concentrations of trace elements in liver and kidneys and clinical chemistry. Comparisons with experimental molybdenosis and copper deficiency in the goat. Sci Total Environ 2000; 249: 107-22. (Pubitemid 30190291)
196. Gibbs KR, Walshe LM. Orphan diseases and orphan drugs. In: Scheinberg IH, Walshe JM, editors. Orphan diseases and orphan drugs. Manchester: Manchester University Press, 1986: 33-42.
197. Cho HY, Blum RA, Sunderland T, et al. Pharmacokinetic and pharmacodynamic modeling of a copper-selective chelator (TETA) in healthy adults. J Clin Pharmacol 2009 Aug; 49 (8): 916-28.
198. Wichmann KA, Boyd PDW, Söhnel T, et al. Characterization of dicarboxylic salts of protonated triethylenete-tramine useful for the treatment of copper-related pathologies. Crystal Growth Design 2007; 7: 1844-50.
199. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
200. Jüllig M, Hickey AJ, Crossman DJ, et al. Reversal of diabetes-evoked changes in mitochondrial protein expression of cardiac left ventricle by treatment with a copper(II)-selective chelator. Proteomics Clin Appl 2007; 1 (4): 387-99.
201. Gong D, Chen X, Middleditch M, et al. Quantitative proteomic profiling identifies new renal targets of copper(II)-selective chelation in the reversal of diabetic nephropathy in rats. Proteomics 2009 Sep; 9 (18): 4309-20.
202. Lu J, Poppitt SD, Othman AA, et al. Pharmacokinetics, pharmacodynamics, and metabolism of triethylenetetramine in healthy human participants: an open-label trial. J Clin Pharmacol 2010 Feb 9; 50 (6): 647-58.
203. Othman A, Lu J, Sunderland T, et al. Development and validation of a rapid HPLC method for the simultaneous determination of triethylenetetramine and its two main metabolites in human serum. J Chromatogr B Analyt Technol Biomed Life Sci 2007 Dec 1; 860 (1): 42-8. (Pubitemid 350161460)
204. Lu J, Chan YK, Gamble GD, et al. Triethylenetetramine and metabolites: levels in relation to copper and zinc excretion in urine of healthy volunteers and type 2 diabetic patients. Drug Metab Dispos 2007 Feb; 35 (2): 221-7. (Pubitemid 46148733)
205. Lu J, Chan YK, Poppitt SD, et al. Determination of triethylenetetramine (TETA) and its metabolites in human plasma and urine by liquid chromatography-mass spectrometry (LC-MS). J Chromatogr B Analyt Technol Biomed Life Sci 2007 Nov 1; 859 (1): 62-8. (Pubitemid 47626085)
206. Persson L. Polyamine homoeostasis. Essays Biochem 2009; 46: 11-24.
207. Pegg AE. Spermidine/spermine-N1-acetyltransferase: a key metabolic regulator. Am J Physiol Endocrinol Metab 2008; 294: E995-1010.
208. Laurent S, Cockcroft J, Van Bortel L, et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006 Nov; 27 (21): 2588-605. (Pubitemid 44627304)
209. Cruickshank K, Riste L, Anderson SG, et al. Aortic pulsewave velocity and its relationship to mortality in diabetes and glucose intolerance: an integrated index of vascular function? Circulation 2002; 106: 2085-90. (Pubitemid 35192814)
210. Jüllig M, Chen X, Vazhoor G, et al. Illuminating the molecular basis of diabetic arteriopathy: a proteomic comparison of aortic tissue from diabetic and healthy rats. Proteomics 2010; 10: 1-10.
211. Jüllig M, Hickey AJ, Middleditch MJ, et al. Characterization of proteomic changes in cardiac mitochondria in streptozotocin diabetic rats using iTRAQ isobaric tags. Proteomics Clin Appl 2007; 1: 565-76.
212. Siddiqui S, Shepherd RE. Electron spin resonance studies of copper(II) polyamine and imidazole complexes. Inorg Chem 1986; 25 (22): 3869-76.
213. Baynes JW, Murray DB. The metal chelators, trientine and citrate, inhibit the development of cardiac pathology in the Zucker diabetic rat. Exp Diabetes Res. Epub 2009 Apr 15.
214. Susztak K, Raff AC, Schiffer M, et al. Glucose induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes 2006; 55: 225-33. (Pubitemid 43343319)
215. Vidotti DB, Arnoni CP, Maquigussa E, et al. Effect of long-term type 1 diabetes on renal sodium and water transporters in rats. Am J Nephrol 2008; 28: 107-14. (Pubitemid 350126500)
216. Verman AS. Roles of aquaporins in kidney revealed by transgenic mice. Semin Nephrol 2006; 26: 200-8.
217. Hryciw DH, Lee EM, Pollock CA, et al. Molecular changes in proximal tubule function in diabetes mellitus. Clin Exp Pharmacol Physiol 2004; 31 (5-6): 372-9. (Pubitemid 38803085)
218. Chuttani HK, Gupta PS, Gulati S, et al. Acute copper sulfate poisoning. Am J Med 1965; 39: 849-54.
219. Franchitto N, Gandia-Mailly P, Georges B, et al. Acute copper sulphate poisoning: a case report and literature review. Resuscitation 2008; 78: 92-6.
220. Nakamura J, Hamada Y, Chaya S, et al. Transition metals and polyol pathway in the development of diabetic neuropathy in rats. Diabetes Metab Res Rev 2002 Sep-Oct; 18 (5): 395-402. (Pubitemid 35256596)
221. Cameron NE, Tuck Z, McCabe I, et al. Effects of the hydroxyl radical scavenger, dimethylthiourea, on peripheral nerve tissue perfusion, conduction velocity and nociception in experimental diabetes. Diabetologia 2001; 44: 1161-9. (Pubitemid 32835509)
222. Smith RG, Heise CC, King JC, et al. Serum and urinary magnesium, calcium and copper levels in insulindependent diabetic women. J Trace Elem Electrolytes Health Dis 1988; 2: 239-43.
223. Ito S, Fujita H, Narita T, et al. Urinary copper excretion in type 2 diabetic patients with nephropathy. Nephron 2001; 88: 307-12. (Pubitemid 32695885)
224. Walter RMJ, Uriu-Hare JY, Olin KL, et al. Copper, zinc, manganese, and magnesium status and complications of diabetes mellitus. Diabetes Care 1991; 14: 1050-6.
225. Hurrell RF, Ribas S, Davidsson L. NaFe3EDTA as a food fortificant: influence on zinc, calcium and copper metabolism in the rat. Br J Nutr 1994; 71: 85-93.
226. National Institute of Standards and Technology. National Institute of Standards and Technology Critically Selected Stability Constants for Metal Complexes Database, Version 6.0 (20899-3460). Gaithersburg (MD): Department of Commerce, 2001.
227. Jonassen HB, Hurst GG, LeBlanc RB, et al. Inorganic complex compounds containing polydentate groups: VI. Formation constants of complex ions of diethylenetetramine and triethylenetetramine with divalent ions. J Phys Chem 1952; 56: 16-9.
228. Tisato F, Marzano C, Porchia M, et al. Copper in diseases and treatments, and copper-based anticancer strategies. Medicinal Res Rev 2010; 30 (4): 708-49.
229. Sajithlal GB, Chithra P, Chandrakasan G. An in vitro study on the role of metal catalyzed oxidation in glycation and crosslinking of collagen. Mol Cell Biochem 1999 Apr; 194 (1-2): 257-63. (Pubitemid 29245567)
230. Sajithlal GB, Chithra P, Chandrakasan G. The role of metal-catalyzed oxidation in the formation of advanced glycation end products: an in vitro study on collagen. Free Radic Biol Med 1998 Aug; 25 (3): 265-9. (Pubitemid 28326200)
231. Birker PJM, Freeman HC. Structure, properties, and function of a copper(I)-copper(II) complex of D-penicillamine: pentathallium(I) mu 8-Chloro-dodeca(Dpenicillaminato) octacuprate(I)hexacuprate(II) n-Hydrate. J Am Chem Soc 1977; 99 (21): 6890-9. (Pubitemid 8255678)
232. Thich JA, Mastropaolo D, Potenza J, et al. Crystal and molecular structure of bis[copper(II) D-penicillamine disulfide] nonahydrate, a derivative of copper(II) cystinate. J Am Chem Soc 1974; 96 (3): 726-31.
233. Tatemichi TK, Desmond DW, Paik M, et al. Clinical determinants of dementia related to stroke. Ann Neurol 1993 Jun; 33 (6): 568-75. (Pubitemid 23161876)
234. Skoog I, Nilsson L, Palmertz B, et al. A population-based study of dementia in 85-year-olds. N Engl J Med 1993 Jan 21; 328 (3): 153-8. (Pubitemid 23021500)
235. Schönberger SJ, Edgar PF, Kydd R, et al. Proteomic analysis of the brain in Alzheimer's disease: molecular phenotype of a complex disease process. Proteomics 2001 Dec; 1 (12): 1519-28.
236. Peila R, Rodriguez BL, Launer LJ. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: the Honolulu-Asia Aging Study. Diabetes 2002 Apr; 51 (4): 1256-62. (Pubitemid 34438377)
237. Ritchie K, Lovestone S. The dementias. Lancet 2002; 360: 1759-66. (Pubitemid 35447916)
238. Palsdottir A, Helgason A, Palsson S, et al. A drastic reduction in the life span of cystatin C L68Q carriers due to life-style changes during the last two centuries. PLoS Genet 2008; 4 (6): e1000099.
239. Loske C, Gerdemann A, Schepl W, et al. Transition metalmediated glycoxidation accelerates cross-linking of betaamyloid peptide. Eur J Biochem 2000 Jul; 267 (13): 4171-8. (Pubitemid 30436113)
240. Kowalik-Jankowska T, Ruta-Dolejsz M, Wisniewska K, et al. Coordination of copper(II) ions by the 11-20 and 11-28 fragments of human and mouse beta-amyloid peptide. J Inorg Biochem 2002 Sep 30; 92 (1): 1-10. (Pubitemid 35291957)
241. Dong J, Atwood CS, Anderson VE, et al. Metal binding and oxidation of amyloid-beta within isolated senile plaque cores: Raman microscopic evidence. Biochemistry 2003 Mar 18; 42 (10): 2768-73. (Pubitemid 36331519)
242. Drew SC, Noble CJ, Masters CL, et al. Pleomorphic copper coordination by Alzheimer's disease amyloid-beta peptide. J Am Chem Soc 2009; 131: 1195-207.
243. Lin CJ, Huang HC, Jiang ZF. Cu(II) interaction with amyloid-beta peptide: a review of neuroactive mechanisms in AD brains. Brain Res Bull 2010 Jul 30; 82 (5-6): 235-42.
244. Squitti R, Lupoi D, Pasqualetti P, et al. Elevation of serum copper levels in Alzheimer's disease. Neurology 2002 Oct 22; 59 (8): 1153-61. (Pubitemid 35192384)
245. Rossi L, Squitti R, Pasqualetti P, et al. Red blood cell copper, zinc superoxide dismutase activity is higher in Alzheimer's disease and is decreased by D-penicillamine. Neurosci Lett 2002 Aug 30; 329 (2): 137-40. (Pubitemid 34880058)
246. Squitti R, Quattrocchi CC, Dal Forno G, et al. Ceruloplasmin (2-D PAGE) pattern and copper content in serum and brain of Alzheimer disease patients. Biomarker Insights 2006; 1: 205-13.
247. Jeynes B, Provias J. The possible role of capillary cerebral amyloid angiopathy in Alzheimer lesion development: a regional comparison. Acta Neuropathol 2006 Oct; 112 (4): 417-27. (Pubitemid 44469162)
248. Jellinger KA, Attems J. Cerebral amyloid angiopathy in Lewy body disease. J Neural Transm 2008; 115 (3): 473-82.
249. Jellinger KA. Prevalence and impact of cerebrovascular lesions in Alzheimer and Lewy body diseases. Neurodegener Dis 2010; 7 (1-3): 112-5.
250. Jellinger KA, Attems J. Prevalence and impact of vascular and Alzheimer pathologies in Lewy body disease. Acta Neuropathol 2008 Apr; 115 (4): 427-36.
251. Chalmers K, Wilcock GK, Love S. APOE epsilon 4 influences the pathological phenotype of Alzheimer's disease by favouring cerebrovascular over parenchymal accumulation of A beta protein. Neuropathol Appl Neurobiol 2003 Jun; 29 (3): 231-8. (Pubitemid 36718171)
252. Attems J, Jellinger KA, Lintner F. Alzheimer's disease pathology influences severity and topographical distribution of cerebral amyloid angiopathy. Acta Neuropathol 2005 Sep; 110 (3): 222-31. (Pubitemid 41430650)
253. Attems J, Lintner F, Jellinger KA. Amyloid beta peptide 1-42 highly correlates with capillary cerebral amyloid angiopathy and Alzheimer disease pathology. Acta Neuropathol 2004 Apr; 107 (4): 283-91. (Pubitemid 38477354)
254. Attems J, Jellinger KA. Only cerebral capillary amyloid angiopathy correlates with Alzheimer pathology: a pilot study. Acta Neuropathol 2004 Feb; 107 (2): 83-90. (Pubitemid 38159295)
255. Alafuzoff I, Thal DR, Arzberger T, et al. Assessment of beta-amyloid deposits in human brain: a study of the BrainNet Europe Consortium. Acta Neuropathol 2009 Mar; 117 (3): 309-20.
256. Maeda A, Yamada M, Itoh Y, et al. Computer-assisted three-dimensional image analysis of cerebral amyloid angiopathy. Stroke 1993 Dec; 24 (12): 1857-64. (Pubitemid 23352716)
257. Nicoll JA, Yamada M, Frackowiak J, et al. Cerebral amyloid angiopathy plays a direct role in the pathogenesis of Alzheimer's disease: pro-CAA position statement. Neurobiol Aging 2004 May-Jun; 25 (5): 589-97; discussion 603-4. (Pubitemid 38686478)
258. Preston SD, Steart PV, Wilkinson A, et al. Capillary and arterial cerebral amyloid angiopathy in Alzheimer's disease: defining the perivascular route for the elimination of amyloid beta from the human brain. Neuropathol Appl Neurobiol 2003 Apr; 29 (2): 106-17. (Pubitemid 36408329)
259. Sveinbjornsdottir S, Sigurdsson S, Aspelund T, et al. Cerebral microbleeds in the population based AGESReykjavik study: prevalence and location. J Neurol Neurosurg Psychiatry 2008; 79: 1002-6.
260. Weller RO, Preston SD, SubashM, et al. Cerebral amyloid angiopathy in the aetiology and immunotherapy of Alzheimer disease. Alzheimers Res Ther 2009; 1 (2): 6.
261. Glenner GG, Wong CW. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 1984 May 16; 120 (3): 885-90. (Pubitemid 14104991)
262. Sparks DL, Schreurs BG. Trace amounts of copper in water induce beta-amyloid plaques and learning deficits in a rabbit model of Alzheimer's disease. Proc Natl Acad Sci USA 2003 Sep 16; 100 (19): 11065-9. (Pubitemid 37140153)
263. Bush AI, Tanzi RE. The galvanization of beta-amyloid in Alzheimer's disease. Proc Natl Acad Sci USA 2002 May 28; 99 (11): 7317-9.
264. Bush AI. The metallobiology of Alzheimer's disease. Trends Neurosci 2003 Apr; 26 (4): 207-14. (Pubitemid 36412003)
265. Cherny RA, Atwood CS, Xilinas ME, et al. Treatment with a copper-zinc chelator markedly and rapidly inhibits betaamyloid accumulation in Alzheimer's disease transgenic mice. Neuron 2001 Jun; 30 (3): 665-76. (Pubitemid 32607332)
266. Squitti R, Salustri C. Agents complexing copper as a therapeutic strategy for the treatment of Alzheimer's disease. Curr Alzheimer Res 2009 Dec; 6 (6): 476-87.
267. Bush AI. Metal complexing agents as therapies for Alzheimer's disease.Neurobiol Aging 2002 Nov-Dec; 23 (6): 1031-8. (Pubitemid 35447784)
268. Brewer GJ. The risks of free copper in the body and the development of useful anticopper drugs. Curr Opin Clin Nutr Metab Care 2008 Nov; 11 (6): 727-32.
269. Ritchie CW, Bush AI, Mackinnon A, et al. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch Neurol 2003 Dec; 60 (12): 1685-91. (Pubitemid 37521621)
270. Cahoon L. The curious case of clioquinol. Nat Med 2009 Apr; 15 (4): 356-9.
271. Lannfelt L, Blennow K, Zetterberg H, et al. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol 2008; 7 (9): 779-86.
272. Di Vaira M, Bazzicalupi C, Orioli P, et al. Clioquinol, a drug for Alzheimer's disease specifically interfering with brain metal metabolism: structural characterization of its zinc(II) and copper(II) complexes. Inorg Chem 2004; 43 (13): 3795-7.
273. Ferrada E, Arancibia V, Loeb B, et al. Stoichiometry and conditional stability constants of Cu(II) or Zn(II) clioquinol complexes; implications for Alzheimer's and Huntington's disease therapy. Neurotoxicol 2007; 28 (3): 445-9. (Pubitemid 46850765)
274. Bush AI. Drug development based on the metals hypothesis of Alzheimer's disease. J Alzheimers Dis 2008; 15 (2): 223-40.
275. McGarry JD.Dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes 2001; 51: 7-18.
276. Anastasiou E, Lekakis JP, Alevizaki M, et al. Impaired endothelium-dependent vasodilatation in women with previous gestational diabetes. Diabetes Care 1998; 21: 2111-5. (Pubitemid 28549159)
277. Meigs JB, O'Donnell CJ, Tofler GH, et al. Hemostatic markers of endothelial dysfunction and risk of incident type 2 diabetes. The Framingham Offspring study. Diabetes 2006; 55: 530-7. (Pubitemid 43343286)
278. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications: part 1. Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998 Jul; 15 (7): 539-53. (Pubitemid 28319935)
279. NAVIGATOR Study Group. Effect of valsartan on the incidence of diabetes and cardiovascular risk. N Engl J Med 2010; 362 (16): 1477-90.
280. Greenstein AS, Paranthaman R, Burns A, et al. Cerebrovascular damage in late-life depression is associated with structural and functional abnormalities of subcutaneous small arteries. Hypertension 2010 Oct; 56 (4): 734-40.
281. Kell DB. Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson's, Huntington's, Alzheimer's, prions, bactericides, chemical toxicology and others as examples. Arch Toxicol 2010; 84: 825-89.
282. Lovell MA, Robertson JD, Teesdale WJ, et al. Copper, iron and zinc in Alzheimer's disease senile plaques. J Neurol Sci 1998; 158: 47-52. (Pubitemid 28277534)
283. Stadler N, Lindner RA, Davies MJ. Direct detection and quantification of transition metal ions in human atherosclerotic plaques: evidence for the presence of elevated levels of iron and copper. Arterioscler Thromb Vasc Biol 2004; 24 (5): 949-54 (Pubitemid 38620877)